Advances in the Diagnosis and Management of Myasthenia Gravis

Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disorder characterized by fluctuating muscle weakness and fatigue caused by impaired transmission at the neuromuscular junction. The disease is most commonly associated with antibodies directed against acetylcholine receptors or other postsynaptic membrane proteins. Recent advances in immunology, neurophysiology, and molecular diagnostics have significantly improved the early detection and management of myasthenia gravis. Modern therapeutic approaches, including immunosuppressive agents, monoclonal antibodies, thymectomy, and individualized treatment strategies, have contributed to better clinical outcomes and quality of life for patients. This article reviews current developments in the diagnosis and management of myasthenia gravis, highlighting recent innovations and future perspectives in patient care.